Applied DNA Sciences, Inc. | Finanzwire

Basculer en Français

8302	Companies
115121	Keywords
55446	Articles
62530	Press releases

Headlines Articles Press releases Applied DNA Sciences, Inc.

Home
Companies
Applied DNA Sciences, Inc.

BRIEF

published on 04/22/2024 at 22:10, 6 months 29 days ago

Applied DNA Announces 1-For-20 Reverse Stock Split

Share Consolidation Reverse Stock Split Applied DNA Sciences NASDAQ:APDN Equity Adjustment
PRESS RELEASE

published on 04/22/2024 at 22:05, 6 months 29 days ago

Applied DNA Announces 1-For-20 Reverse Stock Split
Applied DNA Sciences, Inc. (NASDAQ:APDN) announces 1-for-20 stock split effective April 25, 2024, to regain Nasdaq listing compliance. Proportional adjustments made. For more information, visit adnas.com

Nasdaq Applied DNA Sciences Stock Split Nasdaq Listing Compliance Proportional Adjustments
BRIEF

published on 03/18/2024 at 14:05, 8 months 3 days ago

Applied DNA Sciences Partners with Alphazyme to Scale-Up Manufacturing of Linea™ RNAP

Applied DNA Sciences Alphazyme Linea RNAP MRNA Manufacturing PCR Technology
PRESS RELEASE

published on 03/18/2024 at 14:00, 8 months 3 days ago

Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
Applied DNA Sciences and Alphazyme LLC collaborate to enhance manufacturing of Linea RNA polymerase to meet growing demand for Linea IVT platform. Project aims to increase RNAP manufacturing capacity and reduce unit costs

Manufacturing Applied DNA Sciences Linea IVT Platform Alphazyme LLC Linea RNA Polymerase
BRIEF

published on 03/14/2024 at 15:05, 8 months 7 days ago

Applied DNA to Present Advanced DNA Platforms at World Vaccine Congress

Applied DNA Sciences World Vaccine Congress Linea DNA Platform Linea IVT Platform MRNA Production
PRESS RELEASE

published on 03/14/2024 at 15:00, 8 months 7 days ago

Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
Applied DNA Sciences, Inc. will showcase Linea™ IVT and Linea™ DNA platforms at the 24th Annual World Vaccine Congress in Washington, D.C. Sales team available

Applied DNA Sciences DNA Technologies World Vaccine Congress Linea DNA Linea IVT
PRESS RELEASE

published on 02/08/2024 at 22:05, 9 months 13 days ago

Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
Applied DNA Sciences, Inc. (NASDAQ:APDN) announces Q1 fiscal year 2024 financial results and progress on GMP production capacity for mRNA therapeutics. Projects initial facility capacity to enable up to $15 million Linea IVT revenue annually

Financial Results Applied DNA Sciences MRNA Therapeutics GMP Production Capacity Linea IVT Revenue
PRESS RELEASE

published on 02/05/2024 at 19:00, 9 months 16 days ago

Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
Applied DNA Sciences, Inc. will release first quarter fiscal 2024 financial results after market close on February 8, 2024, with a conference call for analysts. The company operates in biotechnology developing DNA detection and production technologies

Financial Results Conference Call Biotechnology Applied DNA Sciences DNA Detection
PRESS RELEASE

published on 02/02/2024 at 22:15, 9 months 19 days ago

Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Applied DNA Sciences, Inc. closes registered direct offering of common stock priced at-the-market with institutional investors. Proceeds to be used for therapeutic DNA production services

Registered Direct Offering Institutional Investors Common Stock Applied DNA Sciences DNA Technologies
PRESS RELEASE

published on 01/31/2024 at 14:00, 9 months 21 days ago

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Applied DNA Sciences, Inc. announces a registered direct offering and a concurrent private placement to certain existing institutional investors. Maxim Group LLC acts as exclusive placement agent

Registered Direct Offering Applied DNA Sciences Securities Purchase Agreements Maxim Group LLC DNA Technologies

Accesswire

Published on 11/21/2024 at 22:05, 57 minutes ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 1 hour 12 minutes ago

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 47 minutes ago

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 2 hours 52 minutes ago

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 3 hours 2 minutes ago

Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 19:01, 4 hours 1 minute ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 4 hours 26 minutes ago

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 5 hours 3 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 5 hours 10 minutes ago

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 5 hours 10 minutes ago

2CRSi SA: 2CRSi supplies Exaion, a subsidiary of the EDF Group, with high-performance immersion servers in North America.

Les Echos

Published on 11/21/2024 at 06:58, 16 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 1 day 3 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 1 day 5 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 15 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE